CHMP Recommends EU Approval for Novo Nordisk's Wegovy® 7.2 mg Single-Dose Pen for Obesity
NVO sits 27% above its 52-week low of $35.12.
Summary
European regulators have recommended approval for a more convenient single-dose pen version of Novo Nordisk's high-dose Wegovy® (7.2 mg) for obesity, paving the way for an EU launch in Q3 2026.
Key Events · Product Development and Regulatory · NVO
-
Positive CHMP Opinion
The Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Wegovy® 7.2 mg in a single-dose pen for people living with obesity in the EU.
-
Enhanced Convenience
This new formulation offers a more convenient, once-weekly single-dose injection, improving patient experience compared to the current multi-injection regimen for the 7.2 mg dose in the EU.
-
Expected EU Launch
Novo Nordisk anticipates launching the Wegovy® 7.2 mg single-dose pen in the EU in Q3 2026.
-
Proven Efficacy
The 7.2 mg dose demonstrated an average weight loss of 20.7% in the STEP UP trial, with approximately one-third of patients achieving 25% or greater weight loss.
Analysis · NVO · Life Sciences
The positive opinion from the European Medicines Agency's CHMP for the single-dose pen formulation of Wegovy® 7.2 mg is a significant regulatory milestone. This approval enhances patient convenience and adherence for a key growth product in the EU market, potentially boosting sales and market penetration for Novo Nordisk's leading obesity treatment.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVO was trading at $44.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $195.9B. The 52-week trading range was $35.12 to $81.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.